Upload
buiquynh
View
233
Download
0
Embed Size (px)
Citation preview
PRE-FEASIBILITY REPORT
FOR TERMS OF REFERENCES
October, 2016
SRI KRISHNA PHARMACEUTICALS LIMITED PLOT NO. F-1,
MIDC CHINCHOLI,
TALUKA- MOHOL,
SOLAPUR DISTRICT
MAHARASTRA
Studies & Documentation By M/S Pridhvi Enviro Tech pvt. Ltd
Submitted by (MoE&F O.M – S.NO: 122, rev 46,
dated 5.10.2016) Sri Krishna pharmaceuticals Ltd, 184/C, Lawn House Plot No. F-1 Vengal Rao Nagar
MIDC, Chincholi Hyderabad-500038
Taluka Mohol Ph: 040-40179770
Solapur (D) Fax: 040-66730926
Maharastra E-Mail: [email protected]
SUBMITTED TO MINISTRY OF ENVIRONMENT & FORESTS, GOI
PARYAVARAN BHAWAN, CGO COMPLEX,
LODHI ROAD, NEW DELHI-110003
CONTENTS
S.No. Description Page No.
1 Introduction 1
2 Introduction of the project 2
Introduction of the company and the
proponent
3
3 Project Description 4
3.1 Production Capacity 4
3.2 Manufacturing Process 5
3.3 Raw materials 5
3.4 Water Requirement 5
3.5 Waste generation and control systems 6
3.5.1 Liquid effluents 6
3.5.2 Solid waste management 9
4 Site Analysis 10
4.1 Plant location 10
5 Planning in Brief 16
6 Resource requirement 16
6.1 Power requirement and Supply/ Source 16
6.2 Production facilities , Utilities and
effluent handling facilities
16
6.3 Land requirement 17
7 Air pollution 18
8 Bulk chemical storage 18
9 Base line data studies 19
10 Project financial 19
LIST OF TABLES
LIST OF FIGURES
LIST OF ANNEXURES
Table No. Description Page No.
1.0 Salient Features of the Project 2
2.0 List of Proposed Products 4
3.0 Water Balance Proposed 5
4.0 Solid Waste and Disposal 9
5.0 Utilities /ETP-Proposed 16
6.0 Land Statement 17
7.0 Emission Source Proposed 18
8.0 Storage facilities of bulk chemicals 18
Fig No Description Page No.
1.1 Schematic treatment scheme of high
TDS effluents
7
1.2 Low TDS Effluent Treatment System 8
1.3 Topo Map of the Study Area 12
1.4 Base Map of the Study Area 13
1.5 Photographs of current condition of the
site
14
1.6 Site layout plan 15
Annexure Description
I Typical Technical details of proposed products
II List of Raw materials
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1
1
1. Introduction
Sri Krishna Pharmaceuticals Ltd., engaged in manufacturing of Active
Pharmaceutical Ingredients, and Intermediates was established in the year
1975. Research and Development forms the backbone of the organization with
state of the art instrumentation facilities. They have Five manufacturing sites in
India four in Telangana manufacturing bulk drugs & formulations and one in
Maharastra manufacturing Drug intermediates .
Sri Krishna Pharmaceuticals limited proposed to establish a new unit at
Plot. No. F-1, MIDC, Chincholi, Taluka-Mohol, Sholapur District,
Maharastra state.
The unit obtained TOR for the proposed unit from SEAC, Maharastra and
submitted draft EIA Report based on Model TOR’s on April 5th 2014. The
proposed unit is located in Notified industrial Area, MIDC, Chincholi, As
the unit is within 5 KM from the proposed eco sensitive zone of the Nanaj
Sanctuary Great Indian Bustard sanctuary.
In the year 2014, Hon. Supreme Court had given directions to all State
Govts. to finalize the ESZs for all the PAs coming under them. Further,
directions were given by Hon. Supreme Court that in absence of finalized
ESZ or for a period till the ESZ gets finalized, a distance of 10 Km from
the boundary of PA would be treated as ESZ.
Under such circumstances, as per the provisions in MoEF notification
dated 14.09.2006, any project in Cat. B coming in ESZ of a Protected
Area would be treated as Cat. A and hence the State Level EIA Authority
rejected the case and advised the company to approach MOEF in Delhi for
the clearance
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1
2
Hence this application is made for obtaining fresh TOR. As the unit is
located in IE, Chincholi which is notified industrial area established prior
to 2006 notification, Public hearing may be exempted for this unit.
In order to meet the market demand it is now proposed to manufacture 6
API’s with a production capacity of 2545 TPM.
2. Introduction of the Project
The proposed unit is to manufacture Bulk Drugs (APIs) to a tune of 1250
TPA. The salient features of the project are described in the table given
below
TABLE 1.0
Salient Features of the Project
Location F-1, MIDC Chincholi (V), Mohol (Taluk), Solapur (district), Maharashtra
Longitude and Latitude 17o46’20.9’’ N 75o 48’13.0’’ E 17o46’35.3’’ N 75o 48’12.9’’ E 17o46’35.2’’ N 75o 48’05.3’’ E
17o46’20.6’’ N 75o 48’05.5’’ E
Product Category 5(F) Bulk Drugs & Intermediates
Project Category as per EIA notification
Category A (located within 5 Km distance from the proposed ESZ of GIB Nanaj Sanctuary)
Proposed Activity Drugs & Drug intermediates- 2545 TPM
Total investment on the plant Rs. 125 Crores
Total Investment on
Environmental Infrastructure
Rs. 8 Crores
Total area of the plant 25.0 Acres
Total area of green belt 9.3 Acres
Water requirement Total water requirement for project will be 1430 KLD. Fresh water requirement- 973 KLD Recycled water- 457 KLD
Source of water MIDC, Chincholi.
Nearest habitation and distance from the site
Chincholi Village-0.97 Km from the site (S)
Nearest surface water bodies Nanaj Odha is at a distance of 0.83 km from the site
Nearest reserve forest There are no reserve forests in 10 km radius from the site
Environmentally sensitive None
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1
3
areas within 10 km radius
Any national parks, wild life sanctuaries within 10 km
radius
GIB Nanaj Sanctuary is at a distance of 7.68 Kms from the site.
Proposed ESZ of GIB Nanaj Sanctuary- 1.84 Kms
Nearest air port and distance Solapur Airport- 21.3 km
Nearest railway station and distance
Pakni Railway Station-5.76 km
National Highway NH 9 is at a distance of 3.1 Km from the site
i) Introduction of the company and proponent
Sri Krishna Pharmaceuticals Ltd., engaged in manufacture, custom
manufacturing of Active Pharmaceutical Ingredients, and Intermediates was
established in the year 1975. Research and Development forms the backbone of
the organization with state of the art instrumentation facilities. They have four
manufacturing sites in India with a cumulative monthly production capacity of
200 TPM of chemical entities (APIs and APIs formulations about 710 TPM). Sri
Krishna have handled a wide spectrum of chemical unit processes significantly
being plant scale column chromatography, carbohydrate chemistry, natural
product extraction and other complex synthetic chemical reactions for high
purity compounds.
The company recognized the vital role of R & D for becoming successful in the
generic market. The proposed project under consideration would be located at
Plot No. F-1, MIDC, Chincholi, Taluka -Mohol, Dist. Solapur, State –Maharashtra.
state.
The company has Headquarter in Hyderabad, India, and is catering to the ever
growing demand of Active Pharmaceutical Ingredients (API’s) from single State-
of-the-art manufacturing facility. Already established unit in Chincholi MIDC
(Maharashtra) and has built up a reputation for excellence on the foundations of
consistent high quality, a constantly expanding product portfolio and timely
launches of new API’s.
The in-house QC Laboratories are equipped with sophisticated instruments to
assure the quality of the raw materials, intermediates and API’s. The company
believes in quality by design and continuous improvement in all aspects of its
operations. By this endeavor, Sri Krishna Pharma necessitates to recognize in
the global market of Pharmaceuticals as an important partner for API’s.
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1
4
About Proponent
The management at Sri Krishna Pharmaceuticals Limited consists of highly
qualified and richly experienced persons who have given the company the edge
in terms of quality, consistency, timely delivery and ability.
The Group is headed by a technocrat with academic excellence. Dr. V.V. Subba
Reddy, Founder Chairman is a Post Graduate in Technology, Doctorate in
Science and a Post-Doctoral fellow from National Cancer Institute, NIH,
Maryland, USA. He also serves various trade associations, Government bodies
and Institutions as a representative of the pharmaceutical industry in India.
Quality Management: Strict quality control measures, Good Manufacturing
Practices (GMP) are integrated throughout the manufacturing process to ensure
strict adherence to the quality parameters for both in-process and finished
products.
3. Project Description
3.1 Production Capacity SKPL intends to manufacture 2545 TPM of API (Bulk Drug & Intermediates)
products. Product wise capacity is given below:
TABLE 2.0
PROPOSED PRODUCTS & CAPACITY
S.No Name of the Products Quantity in TPM
Remarks
1A Paracetamol- 4 stages 400
Starting from PNCB -4 Stages
1B Paracetamol – 2 stages 1100
Starting from Penultimate stage-2 Stages
2 Ibuprofen 500
3 Metformin 500
4 Domperidone 15
5 Dextromethorphan Hydrobromide
20
6 Omega -3 10
Total 2545
By Product
1 Acetic Acid 1788 Generates in the process and sold to consumers
2 Soap 40.0
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1
5
3.2 Manufacturing Process
Brief process description and process flow charts are given at Annexure I
3.3 Raw Materials List of raw material product wise is given at Annexure II
3.4 Water Requirement The water requirement for process, domestic, gardening, boiler feed & for
cooling water make up is about 1430.0 KLD. The source of water is already
available from existing water works of MIDC and the same is adequate and
satisfactory. The water balance for daily consumption is presented below.
TABLE 3.0 Water Balance–Proposed
S.
No
Stream Water
requirement in KLD
Waste
Water discharge in
KLD
Proposed Method
of Treatment and Disposal
1 Process 566.0 649.0 Stripper, MEE and ATFD (Condensate to RO) Stripper, MEE and ATFD (Condensate to RO)
2 Washings 10.0 10.0
3 Laboratory
washings
1.0 1.0
4 Scrubbers 50.0 50.0
5 Boiler 201.0 20.0 ETP followed by RO ( RO Reject to MEE)
6 DM/Softener 3.0 3.0
7 Cooling & Regeneration
510.0
51.0
8 Domestic 50.0 40.0 Sewage Treatment Plant & reused for
gardening & flushing’s
9 Gardening 39.0 -
Total 1430.0 824.0
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1
6
3.5 Wastes generation and control systems
3.5.1 Liquid Effluents
As detailed in Table 3.0 waste water generation due to process, domestic,
scrubbers, boilers and other activities would be 824.0 KLD. The quantity of
process effluent from the proposed activity will be segregated as high TDS and
low TDS streams.
High TDS and High COD stream would be treated in stripper followed by
MEE and ATFD. The resultant sludge would be disposed to TSDF,
Hyderabad. The Low TDS stream would be treated along with MEE/ATFD
condensates in biological ETP followed by RO. The RO rejects would be fed
back to MEE. The Permeate from RO would be used for cooling tower
make up. Domestic effluents are treated in sewage treatment plant. Thus
the treatment system proposed is based on “Zero Liquid Discharge” (ZLD)
Concept.
The schematic diagrams of ETP proposed are given in Figure 1.1 and
Figure 1.2 below
Pre
-Fe
asi
bil
ity
Re
po
rt
Sri
kri
shn
a P
ha
rma
ceu
tica
ls L
imit
ed
, P
lot
No
. F
-1
7
Fig
1.1
Sch
em
ati
c T
reatm
en
t S
ch
em
e o
f H
igh
TD
S E
fflu
en
ts
E
fflu
en
t fr
om
Pro
cess
an
d
Aq
. D
isti
lla
te t
o
Ce
me
nt
Pla
nt/
TS
DF
Re
cov
ery
Wa
shin
gs,
Scr
ub
be
r
R
O R
eje
ct
To
TS
DF
Co
nd
en
sate
to
B
iolo
gic
al
T
rea
tme
nt
C
on
de
nsa
te t
o B
iolo
gic
al
Tre
atm
en
t
S
lud
ge
to
TS
DF
Eq
ua
liza
tio
n
Ta
nk
ME
E
AT
FD
Str
ipp
er
Ne
utr
ali
zati
on
Ta
nk
Se
ttli
ng
Ta
nk
Pre
-Fe
asi
bil
ity
Re
po
rt
Sri
kri
shn
a P
ha
rma
ceu
tica
ls L
imit
ed
, P
lot
No
. F
-1
8
Fig
1.2
Lo
w T
DS
Eff
luen
t Treatm
en
t S
yste
m
D
om
esti
c e
fflu
en
t
Eff
lue
nts
fro
m u
tili
tie
s &
ME
E c
on
de
nsa
te
Slu
dg
e t
o T
SD
F
Pe
rme
ate
fo
r re
-use
R
eje
cts
to M
EE
Scr
ee
n
Ch
am
be
r
Slu
dg
e H
old
ing
Ta
nk
Ae
rati
on
Ta
nk
2
Eq
ua
liza
tio
n
Ta
nk
Ne
utr
ali
zati
on
Ta
nk
Cla
rifi
er
2 Ho
ldin
g
Ta
nk
Fil
ter
Pre
ss
Slu
dg
e C
ak
e
Ae
rati
on
Ta
nk
1
Cla
rifi
er
1
Sa
nd
filt
er
Ca
rbo
n
Fil
ter
Ult
ra
filt
rati
on
R
O
Scr
ee
n
Ch
am
be
r
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1
9
3.5.2 Solid wastes management
Hazardous and non - hazardous wastes generated from the proposed
project are detailed below. Mode of disposal are also identified and listed.
Adequate storage of hazardous waste is ensured at the site
TABLE 4.0
Solid Wastes and Disposal
S.No
Type of waste Schedule No.
Quantity in TPM
Disposal
Hazardous waste
1 ETP Sludge 34.3 30.0 CHWTSDF
2 MEE salts / ATFD salts and
inorganic residue
34.3 2511.0
CHWTSDF
3 Spent carbon 28.2 47.5 CHWTSDF
4
Distillation bottom Residue/process
sludge
20.3 412.4 Authorized cement Industries/ CHWTSDF
5 Spent solvents 28.5 52.0 CHWTSDF
6 Iron sludge 28.1 580.0 Authorized cement Industries
7 Waste oil 5.1 0.2 Authorized recyclers/
CHWTSDF
8 oil from process 5.1 10.0 Authorized recyclers/
CHWTSDF
9 E- Waste - 0.240 Send to E- waste Recycler
10 Used Lead acid
batteries - 2 Nos.
Return to supplier for
replacement in exchange
Biodegradable waste
1 ETP Bio sludge - 12.9 Composting and used as manure for
gardening
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1
10
Non Biodegradable waste
1 Waste paper - 100.0
Kgs/month Sale
2 Corrugated boxes
- 500.0
Kgs/month Sale
3 Broken glass - 100.0
Kgs/month Sale
4 Decontaminated
used drums -
100.0
Kgs/month Sale
5 Decontaminated HDPE Bags
- 100.0
Kgs/month Sale
6 Coal ash - 280.0 Sale
CHWTSDF facility at Ranjangaon which is at a distance of 200 Km from
the site has agreed to cater the solid waste from the proposed site.
Transport of Hazardous wastes to TSDF is done by the CHWTSDF. In case
other hazardous wastes, authorized recyclers will transport the wastes.
4. Site Analysis
4.1 Plant Location
M/S Sri Krishna Pharmaceuticals Limited, F-1, MIDC, Chincholi(V), Mohol
(T), Solapur(D), Maharastra state. The site is situated at the following
Latitudes and longitudes
17o46’20.9’’ N 75o 48’13.0’’ E
17o46’35.3’’ N 75o 48’12.9’’ E 17o46’35.2’’ N 75o 48’05.3’’ E
17o46’20.6’’ N 75o 48’05.5’’ E
The land area of the plant is 25.0 acres. The nearest habitation from the
site is Chincholi (V) at a distance of 0.97 km. The nearest railway station
located at Pakni 5.76 KM from the Plant. GIB Nanaj Sanctaury which is
ecologically sensitive area is at a distance of 7.68 Km from the site and
the proposed Eco sensitive zone of GIB Sanctuary is at a distance 1.84
Km from the site. There are no reserve forests in 10 Km radius
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1
11
Following are the surroundings of the site
North – MIDC Road and Tara Hydro laboratories
South –MIDC Road
East – Road followed by LR indust–ries
West - Open land and Challa Chlorides
Topo graphic features of the site and 10 KM study area and base map are
given at Fig 1.3 & 1.4.
Plant & Green Belt Photographs are given at Fig. 1.5
Site lay out map is given at Fig 1.6
Pre
-Fe
asi
bil
ity
Re
po
rt
Sri
kri
shn
a P
ha
rma
ceu
tica
ls L
imit
ed
, P
lot
No
. F
-1
12
Fig
1.3
To
po
Sh
eet
of
the 1
0 K
M s
tud
y a
rea
Pre
-Fe
asi
bil
ity
Re
po
rt
Sri
kri
shn
a P
ha
rma
ceu
tica
ls L
imit
ed
, P
lot
No
. F
-1
13
Fig
1.4
Base m
ap
of
the s
tud
y a
rea
Pre
-Fe
asi
bil
ity
Re
po
rt
Sri
kri
shn
a P
ha
rma
ceu
tica
ls L
imit
ed
, P
lot
No
. F
-1
14
Fig
1.5
Pla
nt
Ph
oto
grap
hs
Pre
-Fe
asi
bil
ity
Re
po
rt
Sri
kri
shn
a P
ha
rma
ceu
tica
ls L
imit
ed
, P
lot
No
. F
-1
15
Fig
1.6
Sit
e L
ay O
ut
Pla
n
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1
16
5.0 Planning in Brief
The project is envisaged to be completed by November 2017, and the
production shall be initiated thereon. Consultants are identified for
preparing the detailed project report.
6. Resource requirements 6.1 Power Requirement and Supply/Source
The total power requirement for this proposed project will be 6000 HP.
The required power connection is available from MSEDCL.
In case of emergency, backup of three nos. of DG sets of capacity 1000
KVA each are proposed with acoustic enclosure.
6.2 Production facilities, Utilities and effluent handling facilities
SKPL it is proposed to arrange the production facilities, utilities and
effluents treatment infrastructure with an investment of Rs.125.0 Crores.
The details are outlined in the below table
TABLE 7.0
Production facilities/Utilities/ETP –Proposed
S.NO Details Capacity/
No Proposed
Production facilities
1 Production Blocks Nos 5
2 Clean rooms Nos 1
3 Boiler (coal Fired) TPH 2 x15 & 1x10*
4 DG sets KVA 2 X 1000
5 Cooling tower TR 5000
6 Softener/DM plant M3/hour 2.5
7 Fresh water RO Plant M3/hour 2.5
Effluent handling & treatment facilities
8 Collection tanks-
Storage
KL 400
9 Neutralization tanks KL 10
10 Stripper, MEE, ATFD KLD 2 X 400
11 RO & Biological
treatment
KLD 600
12 Sewage treatment plant KL 40
* 1 X 10 TPH Boiler is stand by boiler
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1
17
6.3 Land Requirement
The unit is proposed to build the plant in 25 Acres of land and out of which
6.0 acres will be built up area and 9.3 acres of green belt will be
developed. Below table provides the land statement. Detailed site lay out
plan outlining proposed activities is given at Figure 1.6
Table 8.0 Land Statement
S.No Purpose Units Extent
1 Built up area Acres 6.0
2 Green belt Acres 9.3
3 Open area Acres 9.7
Total Acres 25.0
7.0 Air Pollution
The Proposed sources of air emissions from the plant are 15 TPH coal
fired Boilers two in number and 10 TPH boiler and 3 X 1000 KVA DG sets.
The process emissions containing Acetic acid & HCl are scrubbed with
caustic and scrubbed waste send to MEE. Below Table gives proposed
emission sources from the plant
Table 9.0 Emission Source Proposed
S.No Proposed Capacity Fuel Anticipated emissions
Control system
1 Process --- -- Acetic acid fumes, HCl
Scrubber
2 Boiler
Stack
15 TPH
(2 nos)
Coal
SPM,SO2 &NOx
Stack Ht 47
meters, cyclone &
Dust collector
3 Boiler
Stack
10 TPH Coal SPM,SO2
&NOx
Stack Ht
41.5 m
cyclone & Dust collector
4 DG sets 3 X 1000
KVA
HSD SPM,SO2
&NOx
Stack height
of 6.3 meters & acoustic
enclosure
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1
18
8.0 Bulk Chemical Storages:
Following bulk chemical storage facilities are proposed
Table No 10.0
Storage facilities of bulk chemicals
S.No Name of the Solvent MOC No Of
Tanks
Storage
Quantity
1 Isopropyl alcohol MS 1 20KL
2 Isobutyl Benzene MS 1 20KL
3 Isobutyl Acetophenone MS 1 20KL
4 Isopropyl Chloro
acetate
MS 1 20KL
5 Acetone MS 1 20KL
6 O-Xylene MS 1 20KL
7 Toluene MS 2 40KL
8 Methanol MS 1 20KL
9 MIBK MS 1 20KL
10 Caustic Lye (48%) MS 2 50KL
11 Sulphuric Acid MS 1 25KL
12 Acetic anhydride Aluminum 4 100KL
13 HCl PP-FRP 2 50KL
14 Liquor ammonia 25% MS 1 25KL
15 Acetic acid SS 4 100KL
16 Ammonia-LIQ cylinders 1 25KL
9. Baseline data studies
We have a unit at B-14/2 in MIDC Chincholi which is in the same MIDC
of the proposed site for which baseline data has been collected during the
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1
19
period of April 2016 to June 2016 so we request you to kindly allow us to
consider the same data for current study.
10. Project Financial
The estimated cost of the proposed project is approximately 125 Crores.
Out of this Rs. 8.0 Crores will be for effluents treatment facilities and rest
for other process equipment and safety equipment
Project cost
Rs. In
Crores
Plant& machinery 50.0
Civil & Structural 20.0
Total 70.0
Pipe lines & insulation
20% on plant &
machinery 14.0
Electricals & instrumentation 10% on plant & machinery 7.0
Erection & commissioning &
painting
8% on plant & machinery and
structures 5.6
Safety & Environment 10.0
Furniture, fixtures, computers, lighting etc 0.5
Total 107.10
Contingencies & pre-operative expenses 17.5
Project cost say 125 Crores
Annexure I
Typical technical details of the proposed products
PARACETAMOL
Process description and flow sheets
Brief manufacturing process of Paracetamol
Stage-1 (Hydrolysis)
Para Nitro Chloro Benzene is treated with aqueous sodium hydoexide at a temperature of 135-
140oC in an autoclave and neutralized with sulphuric acid to get Para Nito Phenol.
Stage- 2 (Reduction)
Para Nitro Phenol is reduced in boiling water under mild acidic condition with iron poweder
and acetic acid to get Para Amino Phenol,
Stage -3 (Acetylation)
Para Amino Phenol is condensed with Acetic Anhydride in aqueous medium to get
paracetamol and acetic acid.
Stage-4 (Purification)
Paracetamol technical is dissolved in hot water, treated with carbon, crystallized to get
Paracetamol with is dred, milled and packed in LDPE lined HDPE bags.
CHEMICAL PATHWAY OF PARACETAMOL SYSNTHESIS
Stage I -P-Nitro Phenol:
Cl
+ 2NaOH + NaCl + H2O
ONa
NO2
161
NO2
PNCB
157.5
Step 2.
ONa
NO2
161
+ 0.5 H2SO4
OH
NO2
+ 0.5 Na2SO4
0.5 x 142
139
Step 1.
2 x 40 58.5 18
Para Nitro Phenol
(PNP)
OH
NO2
+ 18 Fe + 7H2O+ 9FeO + 3Fe3O4+ xCH3COONa + xH2O
82
7 x 139
18x55.84 7x18xCH3COOH + xNaOH
OH
NH2
7 x 109
60 40 6Fe3O3.5(Av)
6 x 223.52
7
Stage -II - P-Amino phenol:
PNP Para Amino Phenol
(PAP)
18
O
O
S T A G E I II - P a ra c e ta m o l T e c h n ic a l
O H
N H 2
+C H 3 C
O
CC H 3
O H
N H C O C H 3
+ C H 3C O O H
6 0
1 5 11 0 21 0 9
P A P A c e tic A n h yd r id e P a ra c e ta m o l
S ta g e - IV - P a ra c e ta m o l P h a rm a
O H
N H C O C H 3
O H
N H C O C H 3
+ S pen t ca rbonA ctiv e C a rbon
Ph a rm a M L
PARACETAMOL
PROCESS FLOW DIAGRAM
4-Nitrochlorobenzene
Caustic soda Lye
Water
Stage I
Sulphuric acid
Aq layer
PNP
PAP ML / Water
Dilute Acetic acid
Iron powder
Caustic soda Lye
Stage II
Iron sludge
Hydros
SMBS Aq layer
PAP PAP ML
Pharma ML
Acetic anhydride
Soda ash
EDTA
Hydros
SMBS
Stage III
Hydrolysis
Conversion of PNCB to Nitrophenol
(PNP)
Neutralisation
Reduction
Conversion of PNP to
Aminophenol (PAP)
Filtration
candle filter
Cooling and Filtration
Pusher Centrifuge
Acetylation
Conversion of 4-Aminophenol
(PAP) to Paracetamol technical
Filtration
Pusher Centrifuge
Process water/Pharma ML
Soda ash
Activated carbon
Hydros
SMBS
Stage IV
Hydros Pharma ML
DM Water
Acetaminophen (Paracetamol) pharma (wet)
Carbon treatment
Filtration through Leaf
filter and Polishing filter
Recrystallisation
(cooling)
Filtration through
Agitated Nutsche Filter
Acetaminophen Technical
Annexure II
List of Raw Materials
List of Raw Materials of Paracetamol (Starting
from PNCB)
S.No Name of raw material
Qty
(Kgs/day)
1 PNCB 16062.7
2 Caustic Lye (48%) 8486.6
3 Sulphuric Acid 5998.5
4 Iron Powder 14476.4
5 Acetic Acid (20%) 6731.7
6 Acetic anhydride 10184.1
7 EDTA 13.3
8 Hydros 26.7
9 SMBS 13.3
10 Activated Corbon 120.0
11 Sodium Hydro Sulphite(Hydros)
13.3
12 Sodium Meta Bisulphite(SMBS) 13.3
13 Caustic flakes 93.3
List of Raw Materials of Paracetamol
(Starting from PAP)
S.No Name of raw material
Qty
(Kgs/day)
1 PAP (1% ) moisture) 29218.0
2 Acetic anhydride 28008.2
3 EDTA 36.7
4 Hydros 73.3
5 SMBS 36.7
6 Activated Corbon 329.9
7
Sodium Hydro
Sulphite(Hydros) 36.7
8
Sodium Meta
Bisulphite(SMBS) 36.7
9 Caustic flakes 256.6
List of Raw Materials of Metformin HCl
S.No Name of raw material
Qty
(Kgs/day)
1 Dicyanodiamide 8866.7
2 Dimethylamino hydrochloride 9566.7
3 Dimethyl formamide 11700.0
4 Toluene 6200.0
5 Methanol 2833.3
6 Activated carbon 533.3
7 Methanol 22700.0
List of Raw Materials of Domperidone
S.No Name of raw material Qty (Kgs/day)
1 Orthophenylene di amine(OPDA) 279.0
2 Methyl Aceto acetate(MAA) 299.5
3 Xylene 1196.0
4 Caustic lye 48 % 247.5
5 Carbon 18.5
6 Conc. HCl 30 % 368.5
7 1- bromo-3-chloro-propane 335.0
8 Toluene 1195.0
9 Potassium carbonate 315.0
10 Conc. HCl 30 % 320.0
11 Caustic lye 48 % 20.0
12 N- Methyl Piperidone 360.0
13 Ethyl chloro formate 480.0
14 CS Flakes 290.0
15 Toluene 1295.0
16 Methanol 505.0
17 Raney Nickel 10.0
18 Ammonia gas 75.0
19 Hydrogen 5.0
20 DCNB 515.0
21 K2 CO3 300.0
22 Toluene 860.0
23 Potassium carbonate 150.0
24 Potssium chloride 160.0
25 Toluene 1435.0
26 Methanol 860.0
27 Raney Nickel 35.0
28 Hydrogen 15.0
29 Urea 255.0
30 Caustic lye 47 % 820.0
31 Ammonium chloride 575.0
32 Carbon 5.0
33 Conc. HCl 30 % 210.0
34 Ammonia 30% 430.0
35 Soda ash 185.0
36 MIBK 1785.0
37 Methanol 4765.0
38 Carbon 20.0
39 Acetic acid 175.0
40 Ammonia 50.0
List of Raw Materials of Ibuprofen
S.No Name of raw material
Qty
(Kgs/day)
1 Mono Chloro acetic acid 11431.8
2 Iso propyl alcohol 8381.8
3 Sulphuric acid 4170.0
4 Sodium bi carbonate 822.2
5 Sodium carbonate 205.6
6 Isobutyl benzene 12884.5
7 Acetyl chloride 8530.3
8 Aluminum chloride 14641.5
9 Conc. Hcl 30% 1273.2
10 Liq Ammonia 25 % 1273.2
11 Sodium metal 3163.8
12 Isopropyl alcohol 41793.8
13 CS Lye 48% 14681.1
14 Sodium dichromate dehydrate 8796.5
15 Sulphuric acid 16204.0
16 Acetone 40741.5
17 N- Hexane 22685.6
List of Raw Materials of Dextromethorphan
Hydrobromide
S.No Name of raw material
Qty
(Kgs/day)
1 2-[1-Cyclohexyl) ethylamine 784.0
2 4- Methoxy phenyl acetic acid 862.7
3 O-xylene 3136.0
4 Phosphorous oxy chloride 1027.3
5 Sodium borohydride 192.7
6 C S lye 48 % 470.7
7 Toluene 1960.0
8 (-) Mandelic acid 687.3
9 Acetone 1764.0
10 Toluene 2085.3
11 Acetone 1254.0
12 C S lye 177.3
13 Toluene 957.3
14 Caustic 210.0
15 Methyl formate 462.7
16 Methanol 509.3
17 Toluene 816.7
18 Phosphoric acid 1474.0
19 Potassium hydroxide 400.0
20 Toluene 1936.7
21 Formaldehyde (40%) 62.7
22 Formic acid 78.7
23 Toluene 752.7
24 40% Hydroboric acid 431.3
25 Activated carbon 3.3
26 Toluene 880.0
27 Conc. HCl 441.3
List of Raw Materials of Omega-3
S.No Name of raw material
Qty
(Kgs/day)
1 Sea water 15984.0
2 Dextrose 8658.0
3 Toluene 3330.0
4 Crude oil 1332.0
5 Alkali Solution 666.0